$GATO
Gatos Silver, Inc. Stock $gato

$gato Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024005761 Filed on February 21, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$6.998M		$25.79M
YoY Change	24.96%		0.13%
Operating Profit
YoY Change
Interest Expense	$0.00		$679.0K
YoY Change	-100.0%		-98.48%
% of Operating Profit
Other Income/Expense, Net	$9.573M		$38.77M
YoY Change	572.73%		682.38%
Pretax Income	$2.575M		$12.97M
YoY Change	206.55%		-19.39%
Income Tax	$43.00K		$114.0K
% Of Pretax Income	1.67%		0.88%
Net Earnings	$2.532M		$12.86M
YoY Change	203.23%		-11.49%
Net Earnings / Revenue
Basic Earnings Per Share	$0.04		$0.19
Diluted Earnings Per Share	$0.04		$0.18
COMMON SHARES
Basic Shares Outstanding	69.18M shares	69.16M shares	69.16M shares
Diluted Shares Outstanding	70.42M shares		69.54M shares

Balance Sheet

Concept	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$70.59M	$55.48M
Short-Term Investments
Other Short-Term Assets	$2.486M	$22.64M
YoY Change	-84.81%	34.21%
Inventory
Prepaid Expenses	$1.379M	$1.914M
Receivables
Other Receivables
Total Short-Term Assets	$73.54M	$78.69M
YoY Change	145.64%	120.73%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$308.2M	$321.9M
YoY Change	-12.64%	-7.44%
Other Assets	$415.0K	$38.00K
YoY Change	730.0%	-36.67%
Total Long-Term Assets	$308.9M	$322.2M
YoY Change	-12.48%	-7.37%
TOTAL ASSETS
Total Short-Term Assets	$73.54M	$78.69M
Total Long-Term Assets	$308.9M	$322.2M
Total Assets	$382.4M	$400.9M
YoY Change	-0.11%	4.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$375.0K	$2.713M
YoY Change	-17.58%	362.97%
Accrued Expenses		$3.031M
YoY Change		9.78%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$183.4M	-$185.9M
YoY Change	-7.36%	-6.47%
Common Stock	$117.0K	$117.0K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$371.8M	$367.5M
YoY Change
Total Liabilities & Shareholders Equity	$382.4M	$400.9M
YoY Change	-0.11%	4.54%

Cashflow Statement

Concept	2024 Q1	2023
OPERATING ACTIVITIES
Net Income	$2.532M	$12.86M
YoY Change	203.23%	-11.49%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	$15.14M	-$12.02M
YoY Change	-468.9%	-182.59%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$59.50M
YoY Change		-99266.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$34.00K	-$9.000M
YoY Change		119.19%
NET CHANGE
Cash From Operating Activities	$15.14M	-$12.02M
Cash From Investing Activities	$0.00	$59.50M
Cash From Financing Activities	-$34.00K	-$9.000M
Net Change In Cash	$15.10M	$38.48M
YoY Change	-468.07%	270.43%
FREE CASH FLOW
Cash From Operating Activities	$15.14M	-$12.02M
Capital Expenditures		$0.00
Free Cash Flow		-$12.02M
YoY Change		-182.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	12974000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	14529000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001517006
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39649
CY2023	dei	Entity Registrant Name EntityRegistrantName	GATOS SILVER, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2654848
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	925 W Georgia Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 910
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Vancouver
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
CY2023	dei	Entity Address Country EntityAddressCountry	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V6C 3L2
CY2023	dei	City Area Code CityAreaCode	(604)
CY2023	dei	Local Phone Number LocalPhoneNumber	424-0984
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	GATO
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	178256662	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69181047	shares
CY2023	dei	Auditor Firm AuditorFirmId	1263
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Toronto, Canada
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55484000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17004000	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	560000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	1773000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	22642000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	16871000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	78686000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	35648000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	321914000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	347793000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	266000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	38000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	60000	usd
CY2023Q4	us-gaap	Assets Assets	400904000	usd
CY2022Q4	us-gaap	Assets Assets	383501000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	33357000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	26358000	usd
CY2023Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	0	usd
CY2022Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	8661000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69181047	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69162223	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	117000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	117000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	553319000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	547114000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185889000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-198749000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	367547000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	348482000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	400904000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	383501000	usd
CY2023	us-gaap	Exploration Expense ExplorationExpense	26000	usd
CY2022	us-gaap	Exploration Expense ExplorationExpense	110000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25688000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25468000	usd
CY2023	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	79000	usd
CY2022	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	180000	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-1500000	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-7900000	usd
CY2023	us-gaap	Interest Expense InterestExpense	679000	usd
CY2022	us-gaap	Interest Expense InterestExpense	433000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	1332000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	154000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5992000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4801000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	38767000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	41852000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	16094000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	114000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1565000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	12860000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12860000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	14529000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	14529000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69163564	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69162223	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69536298	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69309019	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	331222000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2731000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	14529000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	348482000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	367547000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	12860000	usd
CY2023	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	79000	usd
CY2022	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	180000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	5336000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2840000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	33622000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	45230000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1159000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-199000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-266000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	0	usd
CY2022	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	30775000	usd
CY2023	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-1213000	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	180000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6992000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	24632000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	5771000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	13191000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12020000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	14554000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	60000	usd
CY2023	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	59500000	usd
CY2022	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	59500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-60000	usd
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	9000000	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	4000000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	106000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4106000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	122000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	33357000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	26358000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	38480000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10388000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17004000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6616000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55484000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17004000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	417000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	645000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	128000	usd
CY2023Q4	gato	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	2	subsidiary
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates are valuation of stock and stock options; valuation allowances for deferred tax assets; and the fair value of financial instruments and investment in affiliates. At the LGJV, significant items subject to such estimates and assumptions include mineral properties, life of mine revenue and cost assumptions, mineral resource conversion rates to mineral reserves; environmental reclamation and closure obligations and valuation allowances for deferred tax assets.</span></div>
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	691000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	730000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1914000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2890000	usd
CY2023Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	20000000	usd
CY2022Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	13100000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	37000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	151000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	22642000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	16871000	usd
CY2023	gato	Royalty Payment Percentage RoyaltyPaymentPercentage	0.01
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2713000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	586000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3031000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2761000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3215000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1889000	usd
CY2023Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	24000000	usd
CY2022Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	21000000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	387000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69181047	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	10300000	shares
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	5336000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2840000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	604799	shares
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0174
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0439
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0452
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6075
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5767
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5785
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023	us-gaap	Net Income Loss NetIncomeLoss	12860000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	14529000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69163564	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69162223	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69536298	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69309019	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	13606000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	19111000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-632000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3017000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	12974000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	16094000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	114000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1565000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2725000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3380000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	8000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	20000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1298000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-594000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3908000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3410000	usd
CY2023	gato	Effective Income Tax Rate Reconciliation Withholding Tax Amount EffectiveIncomeTaxRateReconciliationWithholdingTaxAmount	0	usd
CY2022	gato	Effective Income Tax Rate Reconciliation Withholding Tax Amount EffectiveIncomeTaxRateReconciliationWithholdingTaxAmount	1565000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	927000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-9000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-323000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	114000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1565000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	18000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	354000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies	5046000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies	1661000	usd
CY2023Q4	gato	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Deferred Share Unit Awards DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsDeferredShareUnitAwards	835000	usd
CY2022Q4	gato	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Deferred Share Unit Awards DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsDeferredShareUnitAwards	461000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	12656000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	21000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	21000	usd
CY2023Q4	gato	Deferred Tax Assets Mineral Properties DeferredTaxAssetsMineralProperties	2009000	usd
CY2022Q4	gato	Deferred Tax Assets Mineral Properties DeferredTaxAssetsMineralProperties	2009000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	19079000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	10234000	usd
CY2023Q4	gato	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Stock Options DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions	9596000	usd
CY2022Q4	gato	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Stock Options DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions	8917000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	4804000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	4129000	usd
CY2023Q4	gato	Deferred Tax Assets Exploration And Development DeferredTaxAssetsExplorationAndDevelopment	0	usd
CY2022Q4	gato	Deferred Tax Assets Exploration And Development DeferredTaxAssetsExplorationAndDevelopment	41000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	260000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	24000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38672000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	39738000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2996000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	769000	usd
CY2023Q4	gato	Deferred Tax Liabilities Accrued Bonus DeferredTaxLiabilitiesAccruedBonus	280000	usd
CY2022Q4	gato	Deferred Tax Liabilities Accrued Bonus DeferredTaxLiabilitiesAccruedBonus	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	1485000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	178000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	218000	usd
CY2023Q4	gato	Deferred Tax Liabilities Exploration And Development DeferredTaxLiabilitiesExplorationAndDevelopment	18000	usd
CY2022Q4	gato	Deferred Tax Liabilities Exploration And Development DeferredTaxLiabilitiesExplorationAndDevelopment	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	769000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	551000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2730000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	769000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	266000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38672000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	39738000	usd
CY2023Q4	gato	Operating Loss Carryforward Subject To Expiration OperatingLossCarryforwardSubjectToExpiration	72408000	usd
CY2023Q4	gato	Operating Loss Carryforward Not Subject To Expiration OperatingLossCarryforwardNotSubjectToExpiration	18343000	usd
CY2023	us-gaap	Exploration Expense ExplorationExpense	26000	usd
CY2022	us-gaap	Exploration Expense ExplorationExpense	110000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25688000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25468000	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	79000	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	180000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	33622000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	45230000	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-1500000	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-7900000	usd
CY2023	us-gaap	Interest Expense InterestExpense	679000	usd
CY2022	us-gaap	Interest Expense InterestExpense	433000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	1332000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	154000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5992000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4801000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	114000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1565000	usd
CY2023Q4	us-gaap	Assets Assets	400904000	usd
CY2022Q4	us-gaap	Assets Assets	383501000	usd
CY2022Q1	gato	Construction Payable Decrease In Estimated Distribution Agreement Construction Costs ConstructionPayableDecreaseInEstimatedDistributionAgreementConstructionCosts	4200000	usd
CY2022Q1	gato	Construction Payable Decrease In Estimated Distribution Agreement Operating Costs ConstructionPayableDecreaseInEstimatedDistributionAgreementOperatingCosts	5500000	usd

Files In Submission

Name	View Source	Status
0001628280-24-005761-index-headers.html	Edgar Link	pending
0001628280-24-005761-index.html	Edgar Link	pending
0001628280-24-005761.txt	Edgar Link	pending
0001628280-24-005761-xbrl.zip	Edgar Link	pending
a2023-11x02xclawbackpoli.htm	Edgar Link	pending
a2023-11x02xclawbackpoli001.jpg	Edgar Link	pending
a2023-11x02xclawbackpoli002.jpg	Edgar Link	pending
a2023-11x02xclawbackpoli003.jpg	Edgar Link	pending
a2023-11x02xclawbackpoli004.jpg	Edgar Link	pending
a2023-11x02xclawbackpoli005.jpg	Edgar Link	pending
a2024leadcontractredacte.htm	Edgar Link	pending
a2024leadcontractredacte001.jpg	Edgar Link	pending
a2024leadcontractredacte002.jpg	Edgar Link	pending
a2024leadcontractredacte003.jpg	Edgar Link	pending
a2024leadcontractredacte004.jpg	Edgar Link	pending
a2024leadcontractredacte005.jpg	Edgar Link	pending
a2024leadcontractredacte006.jpg	Edgar Link	pending
a2024leadcontractredacte007.jpg	Edgar Link	pending
a2024leadcontractredacte008.jpg	Edgar Link	pending
a2024leadcontractredacte009.jpg	Edgar Link	pending
a2024leadcontractredacte010.jpg	Edgar Link	pending
a2024leadcontractredacte011.jpg	Edgar Link	pending
a2024leadcontractredacte012.jpg	Edgar Link	pending
a2024leadcontractredacte013.jpg	Edgar Link	pending
a2024leadcontractredacte014.jpg	Edgar Link	pending
a2024leadcontractredacte015.jpg	Edgar Link	pending
a2024leadcontractredacte016.jpg	Edgar Link	pending
a2024leadcontractredacte017.jpg	Edgar Link	pending
a2024leadcontractredacte018.jpg	Edgar Link	pending
a2024leadcontractredacte019.jpg	Edgar Link	pending
a2024leadcontractredacte020.jpg	Edgar Link	pending
a2024leadcontractredacte021.jpg	Edgar Link	pending
a2024leadcontractredacte022.jpg	Edgar Link	pending
a2024leadcontractredacte023.jpg	Edgar Link	pending
a2024leadcontractredacte024.jpg	Edgar Link	pending
a2024leadcontractredacte025.jpg	Edgar Link	pending
a2024leadcontractredacte026.jpg	Edgar Link	pending
a2024leadcontractredacte027.jpg	Edgar Link	pending
a2024leadcontractredacte028.jpg	Edgar Link	pending
a2024leadcontractredacte029.jpg	Edgar Link	pending
a2024leadcontractredacte030.jpg	Edgar Link	pending
a2024leadcontractredacte031.jpg	Edgar Link	pending
a2024leadcontractredacte032.jpg	Edgar Link	pending
a2024leadcontractredacte033.jpg	Edgar Link	pending
a2024leadcontractredacte034.jpg	Edgar Link	pending
a2024leadcontractredacte035.jpg	Edgar Link	pending
a71019opusa-redacted.htm	Edgar Link	pending
a71019opusa-redacted001.jpg	Edgar Link	pending
a71019opusa-redacted002.jpg	Edgar Link	pending
a71019opusa-redacted003.jpg	Edgar Link	pending
a71019opusa-redacted004.jpg	Edgar Link	pending
a71019opusa-redacted005.jpg	Edgar Link	pending
a71019opusa-redacted006.jpg	Edgar Link	pending
a71019opusa-redacted007.jpg	Edgar Link	pending
a71019opusa-redacted008.jpg	Edgar Link	pending
a71019opusa-redacted009.jpg	Edgar Link	pending
a71019opusa-redacted010.jpg	Edgar Link	pending
a71019opusa-redacted011.jpg	Edgar Link	pending
a71019opusa-redacted012.jpg	Edgar Link	pending
a71019opusa-redacted013.jpg	Edgar Link	pending
a71019opusa-redacted014.jpg	Edgar Link	pending
a71019opusa-redacted015.jpg	Edgar Link	pending
a71019opusa-redacted016.jpg	Edgar Link	pending
a71019opusa-redacted017.jpg	Edgar Link	pending
a71019opusa-redacted018.jpg	Edgar Link	pending
a71019opusa-redacted019.jpg	Edgar Link	pending
a71019opusa-redacted020.jpg	Edgar Link	pending
a71019opusa-redacted021.jpg	Edgar Link	pending
a71019opusa-redacted022.jpg	Edgar Link	pending
amendmentno9topartneragr.htm	Edgar Link	pending
amendmentno9topartneragr001.jpg	Edgar Link	pending
amendmentno9topartneragr002.jpg	Edgar Link	pending
amendmentno9topartneragr003.jpg	Edgar Link	pending
amendmentno9topartneragr004.jpg	Edgar Link	pending
amendmentno9topartneragr005.jpg	Edgar Link	pending
assignmentconsumptiondow.htm	Edgar Link	pending
assignmentconsumptiondow001.jpg	Edgar Link	pending
assignmentconsumptiondow002.jpg	Edgar Link	pending
assignmentconsumptiondow003.jpg	Edgar Link	pending
assignmentconsumptiondow004.jpg	Edgar Link	pending
ceocert10-k20231.htm	Edgar Link	pending
cfocert10-k20231.htm	Edgar Link	pending
eyform10-kconsent.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gato-20231231.htm	Edgar Link	pending
gato-20231231.xsd	Edgar Link	pending
gato-20231231_g1.jpg	Edgar Link	pending
gato-20231231_g2.jpg	Edgar Link	pending
gato-20231231_g3.jpg	Edgar Link	pending
gatos-2023longtermincent.htm	Edgar Link	pending
gato-20231231_cal.xml	Edgar Link	unprocessable
gato-20231231_def.xml	Edgar Link	unprocessable
gato-20231231_lab.xml	Edgar Link	unprocessable
gato-20231231_pre.xml	Edgar Link	unprocessable
gato-20231231_htm.xml	Edgar Link	completed
gatos-2023longtermincent001.jpg	Edgar Link	pending
gatos-2023longtermincent002.jpg	Edgar Link	pending
gatos-2023longtermincent003.jpg	Edgar Link	pending
gatos-2023longtermincent004.jpg	Edgar Link	pending
gatos-2023longtermincent005.jpg	Edgar Link	pending
gatos-2023longtermincent006.jpg	Edgar Link	pending
gatos-2023longtermincent007.jpg	Edgar Link	pending
gatos-2023longtermincent008.jpg	Edgar Link	pending
gatos-2023longtermincent009.jpg	Edgar Link	pending
gatos-2023longtermincent010.jpg	Edgar Link	pending
gatos-2023longtermincent011.jpg	Edgar Link	pending
gatos-2023longtermincent012.jpg	Edgar Link	pending
gatos-2023longtermincent013.jpg	Edgar Link	pending
gatos-2023longtermincent014.jpg	Edgar Link	pending
gatos-2023longtermincent015.jpg	Edgar Link	pending
gatos-2023longtermincent016.jpg	Edgar Link	pending
gatos-2023longtermincent017.jpg	Edgar Link	pending
gatos-2023longtermincent018.jpg	Edgar Link	pending
gatos-2023longtermincent019.jpg	Edgar Link	pending
gatos-formx2023executive.htm	Edgar Link	pending
gatos-formx2023executive001.jpg	Edgar Link	pending
gatos-formx2023executive002.jpg	Edgar Link	pending
gatos-formx2023executive003.jpg	Edgar Link	pending
gatos-formx2023executive004.jpg	Edgar Link	pending
gatos-formx2023executive005.jpg	Edgar Link	pending
gatos-formxdirector2023d.htm	Edgar Link	pending
gatos-formxdirector2023d001.jpg	Edgar Link	pending
gatos-formxdirector2023d002.jpg	Edgar Link	pending
gatos-formxdirector2023d003.jpg	Edgar Link	pending
gatos-formxdirector2023d004.jpg	Edgar Link	pending
gatos-formxdirector2023d005.jpg	Edgar Link	pending
gatos-formxdirector2023n.htm	Edgar Link	pending
gatos-formxdirector2023n001.jpg	Edgar Link	pending
gatos-formxdirector2023n002.jpg	Edgar Link	pending
gatos-formxdirector2023n003.jpg	Edgar Link	pending
gatos-formxdirector2023n004.jpg	Edgar Link	pending
gatos-formxdirector2023n005.jpg	Edgar Link	pending
gatos-formxdirector2023n006.jpg	Edgar Link	pending
gatos-formxexecutive2023.htm	Edgar Link	pending
gatos-formxexecutive2023001.jpg	Edgar Link	pending
gatos-formxexecutive2023002.jpg	Edgar Link	pending
gatos-formxexecutive2023003.jpg	Edgar Link	pending
gatos-formxexecutive2023004.jpg	Edgar Link	pending
gatos-formxexecutive2023005.jpg	Edgar Link	pending
gatos-formxexecutive2023006.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
soxcert10-k20231.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GATO
Gatos Silver, Inc. Stock $gato

2024 Q1 Form 10-K Financial Statement

#000162828024005761 Filed on February 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GATO Gatos Silver, Inc. Stock $gato

2024 Q1 Form 10-K Financial Statement

#000162828024005761 Filed on February 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GATO
Gatos Silver, Inc. Stock $gato